When does genomics become eugenics?
By Eben Kirksey,
Financial Review
| 12. 11. 2020
As the tools to identify human traits and manipulate them become more refined, ideas about normalcy and deviancy, fitness and disability, are subtly changing.
Simply Google “BGI NIFTY” and you will find a slick website from China’s premier genomics company offering new options in the quest for quality children. This screening technology has already been used in more than 62 countries in Asia, Europe, the Americas, and the Middle East.
The NIFTY webpage has a “decision calculator” to see if you should mitigate the risks of your pregnancy. An embedded YouTube video offers a perspective from a young white couple. They talk in British accents about the importance of accuracy, saying that they are willing to pay for the best prenatal care on the market. An older single woman says that this will be her first and perhaps only baby, and she wants to make sure that nothing is wrong.
Previously in China, under the controversial one-child policy, couples were encouraged to make the most of their only shot. Amniocentesis – the insertion of a needle through the abdominal skin into the uterus to extract amniotic fluid which is then tested – was promoted by government experts as part of the practice...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...
